1. Introduction {#sec1-jcm-09-00458}
===============

Diabetes has become a global health burden affecting 425 million people worldwide according to the International Diabetes Federation (IDF) \[[@B1-jcm-09-00458]\]. IDF also estimates that this number will increase to 630 million in 2045. One of the most important medical complications in diabetic population is the diabetic nephropathy (DN). In the western world, one-third of all diabetic individuals are affected by this pathology \[[@B2-jcm-09-00458]\], which is the leading cause of end-stage renal disease (ESRD) \[[@B3-jcm-09-00458],[@B4-jcm-09-00458]\]. Additionally, renal disease is a major cause of cardiovascular morbidity and mortality in patients with diabetes, with this epidemic being likely to drive us to previously unforeseen socioeconomic costs \[[@B5-jcm-09-00458]\]. Therefore, it is urgent to establish new, effective, and safe therapeutic strategies against DN based on the understanding of the intricate molecular mechanisms of the disease.

The current understanding of the pathogenesis of DN recognizes the involvement of a myriad of deviations from normal homeostasis, including hemodynamic abnormalities, that trigger the increase in systemic and intraglomerular pressure, metabolic abnormalities, oxidative stress, fibrosis, and the activation of the renin--angiotensin system (RAS) \[[@B6-jcm-09-00458],[@B7-jcm-09-00458]\]. Several therapeutic interventions have been implemented to slow the progression of DN. However, these approaches have proved insufficient and new strategies are warranted.

Both circulating inflammatory mediators and infiltration of immune cells levels into renal tissue have been found to be increased in animal models and in patients with DN \[[@B8-jcm-09-00458],[@B9-jcm-09-00458],[@B10-jcm-09-00458],[@B11-jcm-09-00458],[@B12-jcm-09-00458],[@B13-jcm-09-00458],[@B14-jcm-09-00458],[@B15-jcm-09-00458],[@B16-jcm-09-00458],[@B17-jcm-09-00458],[@B18-jcm-09-00458]\]. Adhesion molecules and chemokines are also upregulated in diabetic kidneys, highlighting the role of inflammation in the development of renal damage in the setting of diabetes \[[@B18-jcm-09-00458],[@B19-jcm-09-00458],[@B20-jcm-09-00458],[@B21-jcm-09-00458],[@B22-jcm-09-00458],[@B23-jcm-09-00458],[@B24-jcm-09-00458]\]. The understanding of the inflammatory mechanisms involved in the development and progression of this disease will enable the identification of new potential targets and facilitate the design of innovative anti-inflammatory therapeutic strategies. In this review, we focus on the pathogenesis of the proinflammatory molecules and pathways related to the development and progression of DN, and discuss the opportunity of potential new strategies based on the agents that target the inflammation.

2. Inflammation in the Setting of DN {#sec2-jcm-09-00458}
====================================

Chronic low-grade inflammation and activation of the innate immune system are key factors in the pathogenesis of diabetes mellitus \[[@B8-jcm-09-00458],[@B9-jcm-09-00458],[@B10-jcm-09-00458]\]. Diverse inflammatory parameters are elevated in diabetic patients \[[@B11-jcm-09-00458],[@B12-jcm-09-00458],[@B13-jcm-09-00458],[@B14-jcm-09-00458],[@B15-jcm-09-00458]\] and constitute strong predictors of the development of this disease \[[@B16-jcm-09-00458],[@B17-jcm-09-00458],[@B18-jcm-09-00458]\]. Interestingly, an increasing number of studies also suggest that inflammation, together with oxidative stress and fibrosis, are key links in the progression of DN \[[@B19-jcm-09-00458]\], in addition to hemodynamic abnormalities, metabolic derangements, and increased synthesis of neurohumoral factors such as angiotensin II.

Diverse components of the immune system participate in the initiation and progression of DN including adhesion molecules, chemokines, and proinflammatory cytokines. Renal tissue of patients with DN revealed increased levels of inflammatory molecules and the accumulation of high levels of inflammatory cells \[[@B20-jcm-09-00458],[@B21-jcm-09-00458],[@B22-jcm-09-00458],[@B23-jcm-09-00458],[@B24-jcm-09-00458]\]. The concentration of these components increase as nephropathy progresses \[[@B19-jcm-09-00458],[@B25-jcm-09-00458]\], and all of which have been related to increased urinary albumin excretion (UAE) and to clinical markers of glomerular and tubulointerstitial damage \[[@B25-jcm-09-00458],[@B26-jcm-09-00458]\].

2.1. Inflammatory Cell Accumulation in the Kidney {#sec2dot1-jcm-09-00458}
-------------------------------------------------

Immunologic mechanisms play a significant role in development and progression of DN \[[@B27-jcm-09-00458]\], with recruitment and activation of innate immune cells and elaboration of proinflammatory molecules. The expression of chemokines and adhesion molecules is upregulated in renal cells of animal models of diabetes and in patients with diabetes. These molecules are key mediators of renal injury by virtue of their ability to attract circulating white blood cells and facilitate transmigration of these cells into renal tissue. Adhesion molecules include the vascular cell adhesion molecule 1 (VCAM1) and the intercellular adhesion molecule 1 (ICAM1). Both play an important role in the initiation of renal inflammation. These molecules have been abundantly found in renal biopsies obtained from patients with DN, and circulating levels of both have been related to DN progression \[[@B28-jcm-09-00458],[@B29-jcm-09-00458]\]. In mice models, the deletion of the ICAM1 gene ameliorates renal inflammation \[[@B30-jcm-09-00458]\], indicating that ICAM1 contributes to the pathogenesis of DN.

The renal accumulation of monocytes and macrophages has been related to the progression of chronic kidney disease (CKD) \[[@B31-jcm-09-00458]\]. Thereby, this accumulation has been associated with a decline in the glomerular filtration rate (GFR), the manifestation of histological changes, and poor outcomes in DN patients \[[@B20-jcm-09-00458],[@B21-jcm-09-00458],[@B22-jcm-09-00458],[@B23-jcm-09-00458],[@B24-jcm-09-00458],[@B31-jcm-09-00458],[@B32-jcm-09-00458]\]. In addition, infiltrating cells in the renal microenvironment constitute a source of reactive oxygen species (ROS), proinflammatory factors, metalloproteinases, and growth factors, all of which amplify and chronify the inflammatory response and the progression of kidney damage \[[@B33-jcm-09-00458]\].

The inhibition of this inflammatory cell recruitment has been shown to be protective in experimental diabetic nephropathy \[[@B34-jcm-09-00458],[@B35-jcm-09-00458]\]. Mice models with a deletion in macrophage receptors are more resistant to the development of DN through the amelioration of inflammation and the reduction in the levels of albuminuria, mesangial matrix expansion, and transforming growth factor (TGF-) \[[@B36-jcm-09-00458]\].

In a physiologic inflammatory reaction, macrophages linearly progress through the M1 and M2 phases. M1 macrophages initiate the immune response and produce proinflammatory cytokines. Conversely, M2 are responsible of the tissue repair producing either polyamines to induce proliferation or proline to induce collagen. Under chronic inflammatory conditions, this order of events disappears and both forms coexist. Notably, the M1 phenotype is the major macrophage in streptozotocin-induced DN animals \[[@B32-jcm-09-00458],[@B37-jcm-09-00458]\]. Interestingly, the switch from the M1 to the M2 state induced by the deletion of the Toll-like receptor-2, attenuates UAE and the development of renal morphological changes \[[@B37-jcm-09-00458]\]. The mechanisms by which M2 macrophages attenuate the progression of DN and promote kidney repair are unknown.

2.2. Chemokines, Cytokines, and Signaling Pathways Related with Inflammation {#sec2dot2-jcm-09-00458}
----------------------------------------------------------------------------

Together with inflammatory cells, diverse molecules and pathways participate in the development and progression of both systemic and local inflammation in DN. Cytokines and chemokines constitute a group of secreted proteins that regulate much of the immune response. In addition to this role, these molecules exert important pleiotropic actions as cardinal effectors of injury \[[@B38-jcm-09-00458]\]. Moreover, growing evidence supports the role of different metabolic pathways and factors in the activation of inflammatory mechanisms involved in the pathophysiology of DN including the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway, the nuclear transcription factor kappa B (NF-κB), the Rho-Kinase Signaling, and the nuclear factor erythroid 2-related factor 2 (Nrf2) ([Figure 1](#jcm-09-00458-f001){ref-type="fig"}).

### 2.2.1. Chemokines {#sec2dot2dot1-jcm-09-00458}

MCP1---The chemokine monocyte chemoattractant protein 1 (MCP1) is responsible of the migration of the monocytes through the endothelium after the adhesion and is a major factor influencing macrophage accumulation in renal disease patients and in animal models of renal damage \[[@B38-jcm-09-00458]\]. In diabetic patients, MCP1 is upregulated in the glomerular and renal tubular epithelium \[[@B39-jcm-09-00458],[@B40-jcm-09-00458]\]; moreover, urinary levels are strongly associated with the decline of renal function \[[@B41-jcm-09-00458]\]. The expression of MCP1 in renal cells is induced by inflammatory cytokines and constitutes the starting point for the development of glomerular and tubular inflammation. A number of cytokines are involved in the induction of MCP1 expression in the kidney, but several studies point to tumor necrosis factor (TNF) as the most potent inducer. Based on the above data, the MCP1 protein has been proposed as a novel biomarker of tubulointerstitial changes and as predictor of renal progression and prognosis in patients with diabetes \[[@B42-jcm-09-00458]\].

CSF1---The chemokine colony-stimulating factor 1 (CSF1) governs the survival, proliferation, and differentiation of macrophages. Although CSF1 is constitutively expressed in diverse renal cellular types (glomerular mesangial, tubular, and endothelial cells), the disarrangement in the renal levels of this chemokine in chronic inflammation is involved in the progression of renal disease by generating an uncontrolled intrarenal amplification of macrophages. Renal CSF1 is highly expressed in type 2 diabetic *db/db* mice \[[@B43-jcm-09-00458]\]. Interestingly, decreasing the levels of renal CSF1, by deletion of the codifying gene in mice, attenuates the infiltration and proliferation of macrophages during renal inflammation \[[@B44-jcm-09-00458]\]. The accumulation of macrophages is also attenuated in diverse animal models of renal diseases by the administration of an antibody against the receptor of CSF1 \[[@B45-jcm-09-00458]\]. The regulation of the levels of this factor raises the possibility of specific therapies for targeting macrophage-mediated injury in DN.

### 2.2.2. Inflammatory Cytokines {#sec2dot2dot2-jcm-09-00458}

TNF---The cytokine TNF is mainly produced by monocytes but also, in a lower extent, by renal cells (endothelial, epithelial, mesangial, and tubular cells) \[[@B46-jcm-09-00458],[@B47-jcm-09-00458],[@B48-jcm-09-00458]\]. TNF plays a significant role in the progression of renal disorders \[[@B48-jcm-09-00458]\] interacting with the kidney in a paracrine or autocrine manner \[[@B48-jcm-09-00458],[@B49-jcm-09-00458],[@B50-jcm-09-00458],[@B51-jcm-09-00458]\]. Serum and urinary levels of TNF are increased in patients with DN when compared with nondiabetic individuals or with diabetic subjects without renal disease. Importantly, the increase in TNF levels is related with the development and progression of renal disease in patients with diabetes \[[@B52-jcm-09-00458],[@B53-jcm-09-00458]\]. The expression levels of TNF protein are also enhanced in renal glomeruli and tubules of animal models of diabetes \[[@B53-jcm-09-00458],[@B54-jcm-09-00458],[@B55-jcm-09-00458],[@B56-jcm-09-00458],[@B57-jcm-09-00458]\]. Hypertrophy and hyperfiltration are prominent signs in DN and both have been related to increased TNF expression levels. Several harmful effects are elicited in the kidney by TNF including cytotoxicity \[[@B58-jcm-09-00458]\], apoptosis, and necrotic cell death \[[@B59-jcm-09-00458],[@B60-jcm-09-00458]\]. TNF also alters the equilibrium between vasoconstriction and vasodilation, changing the permeability of endothelial cells, which leads to alterations of intraglomerular blood flow and reductions in GFR \[[@B61-jcm-09-00458]\]. Moreover, TNF directly prompts the formation of ROS in the renal cells independently of hemodynamic mechanisms, altering the glomerular capillary wall and consequently, increasing UAE \[[@B62-jcm-09-00458],[@B63-jcm-09-00458],[@B64-jcm-09-00458]\]. Finally, TNF stimulates sodium retention that might induce the expression of TFG- and consequently, the development of renal hypertrophy \[[@B65-jcm-09-00458],[@B66-jcm-09-00458]\]. These harmful effects can be abrogated by a soluble TNF receptor fusion protein, by blockers of the renal epithelial sodium channel, such as amiloride, and by inhibitors of extracellular signal-related protein kinase.

IL6---The levels of the cytokine interleukin (IL) 6 are also increased in patients with DN when comparing to diabetic patients without renal disease \[[@B67-jcm-09-00458]\]. Kidneys of patients with DN also present increased expression levels of IL6 in infiltrating cells from the mesangium, interstitium, and tubules. Diverse abnormalities at kidney level have been associated with the raise in the expression of IL6 including changes in the permeability of glomerular endothelium, expansion of the mesangium, increased fibronectin levels \[[@B68-jcm-09-00458],[@B69-jcm-09-00458]\], and thickness of the glomerular basement membrane \[[@B70-jcm-09-00458],[@B71-jcm-09-00458]\]. Renal cells of diabetic kidneys also express increased levels of IL6 and experimental studies in animal models with diabetes positively associated this expression with the urinary concentration of this cytokine and with the development of renal hypertrophy \[[@B54-jcm-09-00458],[@B55-jcm-09-00458]\].

IL18---Serum and urinary levels of the cytokine IL18 are increased in DN, being significantly correlated with UAE levels \[[@B52-jcm-09-00458],[@B72-jcm-09-00458],[@B73-jcm-09-00458]\]. IL18 is a potent proinflammatory cytokine with pleiotropic functions including the synthesis of diverse molecules involved in the inflammatory process like IL1 and TNF, the release of interferon- (IFN-) \[[@B74-jcm-09-00458]\], which stimulates functional chemokine receptor expression in mesangial cells \[[@B75-jcm-09-00458]\], the increase in the expression of ICAM1, and the apoptotic process in endothelial cells \[[@B76-jcm-09-00458],[@B77-jcm-09-00458],[@B78-jcm-09-00458]\]. Renal tubular cells express increased levels of IL18 in patients with DN \[[@B79-jcm-09-00458]\], which has been related to the triggering of mitogen-activated protein kinase (MAPK) pathways secondary to the action of TGF- \[[@B80-jcm-09-00458]\]. Moreover, infiltrating cells in the renal tissue also produce this cytokine \[[@B81-jcm-09-00458],[@B82-jcm-09-00458]\].

### 2.2.3. Inflammatory Signal Transduction {#sec2dot2dot3-jcm-09-00458}

Several signaling cascades play a critical role in the development and progression of renal inflammation. These pathways transduce the signals of diverse upstream mediators including oxidative stress, angiotensin II, and advanced glycation end products (AGEs), resulting in a decline in renal function.

JAK/STAT pathway---The JAK proteins are a family of intracellular, non-receptor, tyrosine kinases that transduce extracellular signals after binding to the membrane receptors. The JAK proteins associated with the intracellular domain of the receptor are then phosphorylated and activated. JAK/STAT family is comprised of four tyrosine kinases (JAK1-3 and TYK2) and seven transcription factors (STAT1-4, 5a, 5b and 6), with particular cell-specific combinations identified for each receptor type \[[@B83-jcm-09-00458]\]. The phosphorylated JAK proteins suffer a conformational modification, allowing the transduction of the intracellular signal by further phosphorylating and activating the STAT transcription factors. The activated STAT molecules translocate to the cell nucleus, where they activate many target genes. The JAK/STAT pathway plays a critical role in diverse renal cell types, transducing diverse signals from extracellular ligands including cytokines, chemokines, growth factors, and hormones \[[@B84-jcm-09-00458]\]. The activation of JAK/STAT is an important mechanism by which hyperglycemia contributes to renal damage participating in the pathogenesis of DN through its participation in several processes, such as the hypertrophy of mesangial cells induced by angiotensin Ⅱ, and the synthesis of TGF-, collagen Ⅳ, and fibronectin. In animal models of DN, it has been demonstrated that hyperglycemia is able to turning on the JAK/STAT pathway in the glomeruli and tubulointerstitial cells \[[@B85-jcm-09-00458],[@B86-jcm-09-00458],[@B87-jcm-09-00458],[@B88-jcm-09-00458],[@B89-jcm-09-00458],[@B90-jcm-09-00458]\]. Similarly, gene and protein expression studies of kidney biopsies from patients with early or advanced stages of DN have shown increased activation and expression of the of JAK/STAT \[[@B89-jcm-09-00458],[@B91-jcm-09-00458]\]. In these patients, the increment in mRNAs levels of many JAK/STAT components in the glomerular and tubulointerstitial compartment was inversely correlated with the estimated GFR \[[@B89-jcm-09-00458]\]. Moreover, gene expression and activity of JAK1 and JAK2 have been related to the progression of DN \[[@B84-jcm-09-00458]\].

The proposed mechanism by which hyperglycemia activates the JAK/STAT pathway is through the activation of the activity of JAK proteins caused by ROS under high glucose conditions. Diphenylene iodonium, an inhibitor of ROS formation, results in a marked inhibition of angiotensin Ⅱ (Ang Ⅱ)-induced activation of JAK proteins in human cardiomyocytes \[[@B90-jcm-09-00458]\]. These results reveal that oxidative stress acts as an intracellular activator of the JAK/STAT pathway, and that ROS also acts as a second messenger for the regulation of JAK proteins activation by Ang Ⅱ. Hyperglycemia also increases JAK proteins tyrosine phosphorylation by the alteration of tyrosine phosphatases (SHP-1 and SHP-2) activity. SHP-1 phosphorylation is abolished and SHP-2 phosphorylation is increased under hyperglycemia, suggesting that JAK sustained activation under hyperglycemia is partly due to decreased SHP-1 and increased SHP-2 phosphorylation \[[@B85-jcm-09-00458],[@B86-jcm-09-00458],[@B87-jcm-09-00458],[@B88-jcm-09-00458],[@B89-jcm-09-00458],[@B90-jcm-09-00458]\].

The tyrosine kinase inhibitor of JAK proteins AG490 is able to abrogate the elevation of systolic blood pressure and the increase of UAE \[[@B92-jcm-09-00458],[@B93-jcm-09-00458]\] in animal models of DN. The proteins suppressors of cytokine signaling (SOCS), a group of molecules that bind and interfere with initiating JAK proteins, are important regulators of JAK/STAT activation in DN. Overexpression of SOCS in human mesangial and tubular cells under high concentrations of glucose reversed the glucose-induced activation of this pathway, the expression of STAT-dependent genes and cell proliferation \[[@B94-jcm-09-00458]\]. Similarly, the inoculation of recombinant SOCS1 and SOCS3 adenovirus to diabetic rats improved renal function and reduced mesangial expansion, fibrosis and macrophages renal infiltration. However, further research into JAK inhibitors, SOCS expression or SOCS mimetics is required, given the critical immunomodulatory role of this pathway, with possible adverse effects.

NF-kB---NF-kB constitutes a family of transcription factors that regulates the expression of genes involved in different processes, such as the immune response, cell differentiation and development, apoptosis, cycle progression, inflammation, and tumorigenesis. This pathway is considered one of the major inflammatory pathways involved in DN. NF-κB is continuously present in cells in an inactive state forming a complex with inhibitors of NF-κB (IκBs). Cell surface receptors such as toll-like receptors (TLRs), respond to extracellular stimuli, including hyperglycemia, AGEs, mechanical stress, oxygen radicals, cytokines, angiotensin II, and albuminuria/proteinuria \[[@B95-jcm-09-00458],[@B96-jcm-09-00458],[@B97-jcm-09-00458],[@B98-jcm-09-00458]\]. Many of this signaling molecules that produce the activation of NF-κB are potential targets for the inhibition of this factor and the subsequent inflammatory response. Upon receptors stimulation, IκB-kinases are activated leading to phosphorylation of IκBs which results in polyubiquitination, a sign for destruction of the IκB by proteasome. After this, activated NF-κB enters the nucleus and stimulates the transcription of adhesion molecules, chemokines, inflammatory cytokines, and other molecules related to inflammation and proliferation, all of which are involved in the progression of DN \[[@B96-jcm-09-00458]\]. The activation of NF-κB has been observed in cells of the proximal tubule \[[@B97-jcm-09-00458],[@B98-jcm-09-00458]\] and in renal cortical tissue of experimental models of DN \[[@B43-jcm-09-00458]\]. Proteinuria also stimulates the activation of NF-κB, constituting an important pro-inflammatory stimulus in renal tubular cells \[[@B97-jcm-09-00458]\]. The expression of chemoattractant and adhesive molecules via activation of NF-κB-dependent pathways is also upregulated by excess ultra-filtered protein load in proximal tubular cells \[[@B99-jcm-09-00458]\].

The blockade of RAS in diabetic rats provides renoprotective anti-inflamatory effects through the suppression of NF-κB-dependent pathways, beyond the control of blood pressure and proteinuria \[[@B100-jcm-09-00458]\]. Other drugs such as thiazolidinedione, a peroxisome proliferator activated receptor- (PPAR-), have been also associated to a suppressive effect on the activation of NF-κB \[[@B101-jcm-09-00458],[@B102-jcm-09-00458]\], which was related with an attenuation in renal injury also in diabetic rats. In addition, recent experimental studies indicate that suppression of NF-κB activation by various agents, such as 1,25-dihydroxyvitamin D3 \[[@B103-jcm-09-00458]\], cilostazol \[[@B104-jcm-09-00458]\], and curcumin \[[@B105-jcm-09-00458]\], could lead to amelioration of DKD, suggesting the importance of NF-κB as a therapeutic target of DKD.

Rho-Kinase Signaling---The Rho-associated coiled-coil containing protein kinase (Rho-kinase) is a serine-threonine kinase involved in the regulation and cell proliferation, contraction, and migration of cells by acting on the cytoskeleton. The activation of the Rho-kinase signaling have been associated with renal and cardiovascular diseases. Importantly, the activation of this pathway increases MCP1 levels and the chemotaxis of monocytes toward glomerular cells. Moreover, Rho-kinase is also an important regulator of CSF1 production. In mouse models of DN, the experimental inhibition of this pathway reduces UAE, glomerular expansion \[[@B106-jcm-09-00458],[@B107-jcm-09-00458]\], and the infiltration of macrophages \[[@B41-jcm-09-00458]\]. Similar to the blockade of the JAK/STAT pathway, the inhibition of the Rho-kinase signaling constitutes a new therapeutic anti-inflammatory intervention through reduction of macrophage accumulation in the kidneys.

Experimental studies suggest the existence of a mechanistic linkage between Rho-kinase and NF-κB signaling. Rho-kinase is involved in the endothelial activation of NF-κB by thrombin \[[@B108-jcm-09-00458]\], and lysophosphatidic acid \[[@B109-jcm-09-00458]\], and by neuropeptide in colonic epithelial cells \[[@B110-jcm-09-00458]\]. In experimental mice model of renal failure by lipopolysaccharide injection, Rho kinase inhibition attenuated kidney injury in part by attenuation of NF-κB signaling \[[@B111-jcm-09-00458]\]. All these findings point to Rho-kinase as a new therapeutic target against renal inflammation through a reduction in NF-κB activation.

Nrf2---The transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) is one of the most important regulators of oxidative stress. Nrf2 regulates the expression of antioxidant cytoprotective genes that attenuate systemic oxidative overload. Moreover, activation of Nrf2 reduces renal inflammation by suppressing macrophage inflammatory response by blocking the transcription of pro-inflammatory cytokines including IL1 and IL6 \[[@B112-jcm-09-00458]\]. In experimental mice models of diabetes, the activation of Nrf2 provides atheroprotection through reducing cytokine production and M1 macrophage accumulation \[[@B113-jcm-09-00458]\]. Furthermore, activated Nrf2 exerts protective effects against pathological changes in the glomerulus and attenuates mesangial hypertrophy induced by high glucose \[[@B114-jcm-09-00458]\].

3. New (and Old) Therapies Targeting Inflammation in DN {#sec3-jcm-09-00458}
=======================================================

Tight glycemic control is the primary strategy for the prevention of the development of diabetic complications, and micro- and macrovascular complications \[[@B115-jcm-09-00458]\]. The current practice for the treatment of the established DN is based on two pillars: the metabolic regulation and the blood pressure control, with the RAS blockade as the cornerstone therapy \[[@B116-jcm-09-00458],[@B117-jcm-09-00458]\]. This blockade is therapeutically achieved using RAS blockers such as angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs). This approach effectively slows the progression of the nephropathy both in diabetic and nondiabetic patients. Unfortunately, this approach rarely stops the progression towards the ESRD. Furthermore, the combination of RAS blockers has not been shown to be more effective against the progression of renal disease.; on the contrary, it has been associated with an increase in adverse events. \[[@B115-jcm-09-00458],[@B116-jcm-09-00458],[@B117-jcm-09-00458],[@B118-jcm-09-00458],[@B119-jcm-09-00458]\]. Therefore, new approaches are necessary to delay the development and the progression of the DN, to improve kidney function and to overcome the setbacks with recent trials designed to find effective renoprotection in diabetic patients \[[@B119-jcm-09-00458],[@B120-jcm-09-00458],[@B121-jcm-09-00458],[@B122-jcm-09-00458],[@B123-jcm-09-00458]\]. In this sense, new antidiabetic drugs or old drugs with new uses outside the scope of the original indication have appeared as promising candidates showing beneficial renal effects in DN patients ([Table 1](#jcm-09-00458-t001){ref-type="table"}).

Although the main therapeutic strategy against the development of DN remains directed toward optimizing the control of the major risk factors including hypertension, hyperglycemia, and dyslipidemia \[[@B149-jcm-09-00458]\], recent studies indicate that most successful strategies must also contain immune-targeting properties that limit the inflammation \[[@B150-jcm-09-00458]\]. Interestingly, several renoprotective treatments currently used in patients with DN have anti-inflammatory effects. Therapeutic RAS blockade reduce proteinuria and effectively slow the progression of diabetic and nondiabetic nephropathies by hemodynamic/antihypertensive but also by anti-inflammatory/antifibrotic actions. The reduction in the inflammatory process is mediated by the inhibition of NF-𝜅B dependent pathways \[[@B124-jcm-09-00458]\], a transcription regulator protein complex that regulate inflammatory signals \[[@B151-jcm-09-00458]\]. Downstream targets of NF- B include adhesion molecules and pro-inflammatory cytokines, all of them related with the development of DN: IL6, TNF𝛼, MCP1, and RANTES (Regulated on Activation, Normal T Cell Expressed and Secreted). Methyl bardoxolone selectively reduces the DNA binding of NF-𝜅B by activating powerful Nrf2-dependent phase 2 inducers, thereby inhibiting the inflammatory reaction \[[@B125-jcm-09-00458]\]. Treatment with this compound improved renal function in DN patients in the short- and long-term in a dose-related manner \[[@B152-jcm-09-00458]\] but, unfortunately, phase III clinical trial yielded serious adverse events and hence, the trial was stopped.

The anti-inflammatory effect elicited by the RAS blockade could be related to the therapeutic efficacy of the RAS inhibitors used in the treatment of DN \[[@B153-jcm-09-00458],[@B154-jcm-09-00458],[@B155-jcm-09-00458],[@B156-jcm-09-00458]\]. However, new agents that specifically target the inflammatory phenomena offers new therapeutic opportunities. The manipulation of the pro-inflammatory chemokine MCP1 signaling axis constitutes one of these opportunities. The administration of the MCP1 antagonizing L-RNA aptamer (Spiegelmer^®^) to uninephrectomized db/db mice, significantly reduced glomerular macrophages infiltration while improved diffuse glomerulosclerosis and inhibited the decline in glomerular filtration rate \[[@B157-jcm-09-00458]\]. The blockade of the MCP1 receptor with other compounds produced similar results in the db/db model \[[@B158-jcm-09-00458],[@B159-jcm-09-00458],[@B160-jcm-09-00458]\]. These results have substantiated the hypothesis that blocking the actions of MCP1 might constitute a new therapeutic anti-inflammatory target in DN. At present time, a phase 2, placebo-controlled clinical trial designed to evaluate the safety and tolerability as well as the renoprotective potential of the MCP1 antagonist emanticap pegol in DN, is underway \[[@B126-jcm-09-00458]\]. Emanticap pegol specifically binds and inhibits MCP1. Treatment was able to decrease UAE respect to baseline even after cessation of the intervention, without differences from the placebo group \[[@B126-jcm-09-00458]\].

Otherwise, the inhibition of the JAK/STAT pathway, which is an important regulator for transducing signals from cytokines and chemokines in renal cells \[[@B85-jcm-09-00458]\] is another anti-inflammatory target to reduce glomerular hypertrophy and the decline in the GFR \[[@B161-jcm-09-00458]\]. Diverse drugs and compounds under investigation have shown anti-inflammatory effects via inhibition of the JAK/STAT pathway in experimental DN \[[@B162-jcm-09-00458],[@B163-jcm-09-00458]\]. The Chinese herbal granule Tangshen Formula improves proteinuria and eGFR in patients with type 2 diabetes mellitus \[[@B164-jcm-09-00458]\]. Results of a Phase 2 multicenter, randomized, multi-dose, placebo-controlled, clinical trial (NCT01683409) demonstrated that the oral drug Baracitinib, which selectively inhibits JAK1 and JAK2, attenuated UAE in a dose dependent manner in patients with DN with residual macroalbuminuria on RAS blockade, demonstrating its potential utility in the treatment of DN \[[@B85-jcm-09-00458]\]. A total of 129 participants were randomly selected to receive placebo or different doses of Barcitinib (0.75, 1.5, or 4 mg) for 24 weeks, followed by a 4 weeks wash-out period. Baricitinib (4 mg/day) significantly reduced albuminuria at weeks 12 and 24 and after 4 weeks of washout compared with placebo. Importantly, Baricitinib also decreased the blood levels of the inflammatory biomarkers ICAM1, TNFR 1 and 2, serum amyloid A, and the urine levels of MCP1 \[[@B84-jcm-09-00458]\]. In addition to the suppression of specific signaling pathways related with inflammation, a few novel anti-diabetic drugs have aroused great interest from scientific researchers. These drugs have been demonstrated to improve albuminuria and other traits of DN in type 1 and 2 diabetes and to exert anti-inflammatory actions that potentially could delay the progression of DN. The group of sodium-glucose cotransporter-2 (SGLT2) inhibitors are promising hypoglycemic agents that have the added advantage of not promoting hyperinsulinemia, weight gain, or hypoglycemia, unlike traditional antidiabetic agents \[[@B165-jcm-09-00458]\]. Their mode of action lies in the effective blockade of glucose reabsorption by SGLT2 at the proximal tubule; thereby, causing glucosuria and reducing blood glucose levels, independently of the insulin action \[[@B166-jcm-09-00458]\]. Beyond glycemic control, secondary outcome analyses of these drugs in cardiovascular safety trials have shown potent renoprotective effects. In particular, slower progression of kidney disease and lower rates of clinically relevant renal events have been reported for empagliflozin in the prospective empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes (EMPA-REG OUTCOME) trial \[[@B167-jcm-09-00458]\] comparing the administration of SGLT2 inhibitor with placebo. Similar results were observed, two years later, in the canagliflozin cardiovascular assessment study (CANVAS) \[[@B168-jcm-09-00458]\]. The results of the dedicated renal trial canagliflozin and renal end points in diabetes with established nephropathy clinical evaluation (CREDENCE) have recently confirmed the effects of SGLT2 inhibitors on the decline of kidney function \[[@B169-jcm-09-00458]\]. Although only few studies have focused on the underlying mechanisms explaining the cardiovascular and renal protection exerted by these drugs \[[@B170-jcm-09-00458],[@B171-jcm-09-00458],[@B172-jcm-09-00458]\], SGLT2 inhibitors are thought to potentially target inflammation \[[@B173-jcm-09-00458]\]. In this sense, the administration of canakinumab to high-risk population directly confers cardiovascular benefits and reduces inflammation by targeting the interleukin-1-beta (IL-1) innate immunity. These results were recently reported in the canakinumab anti-inflammatory thrombosis outcome study (CANTOS) \[[@B127-jcm-09-00458]\]. A secondary analysis of CANTOS also reported that the reduction of high-sensitivity C-reactive protein (hsCRP) is a good predictor of beneficial effects on cardiovascular outcomes \[[@B128-jcm-09-00458]\].

A few smaller pilot studies have also pointed to a reduction of inflammatory markers in patients with type 2 diabetes after the administration of SGLT2 inhibitors. Reductions in serum levels of hsCRP, TNF, IL6, and interferon-γ (IFN-γ) have been observed after administration of canagliflozin, dapagliflozin, and empagliflozin \[[@B129-jcm-09-00458],[@B130-jcm-09-00458],[@B131-jcm-09-00458],[@B132-jcm-09-00458],[@B133-jcm-09-00458],[@B134-jcm-09-00458],[@B135-jcm-09-00458]\]. However, most of these reductions did not reach statistical significance, probably because of the limited number of patients. Solid data of short- and mainly long-term SGLT2 inhibitors anti-inflammatory actions in DN, are still needed. Meanwhile, experimental studies point to the existence of this immunomodulatory effect in DN mediated by the reduction in glucose transport into proximal tubular cells and the subsequent appearing of glucotoxicity, oxidative stress, and inflammation, but also by controlling the gene expression of inflammatory molecules by unknow mechanisms. Administration of and SGLT2 inhibitor reduces albuminuria and tubulointerstitial injury in obese diabetic mice \[[@B174-jcm-09-00458],[@B175-jcm-09-00458],[@B176-jcm-09-00458]\]. In HK2 cells (human kidney proximal tubule cell line), empagliflozin attenuates high glucose-induced expression of Toll-like receptor-4, binding of nuclear deoxyribonucleic acid to NF-κB, and secretion of collagen IV and IL6 \[[@B177-jcm-09-00458]\]. In the atherosclerosis mice model ApoE -/-, empagliflozin reduces the expression of inflammatory mediators such as TNFα, IL1β, and IL6 as well as the infiltration of cells into atheromatous plaques \[[@B178-jcm-09-00458]\]. In animal models with type 1 diabetes, empagliflozin treatment achieved a reduction in NF-κB, MCP1, and IL6 renal levels that was related with the reduction in albuminuria \[[@B179-jcm-09-00458]\]. In type 2 diabetes mice models, the inhibition of SGLT2 also reduced glomerular macrophage infiltration and glomerular sclerosis \[[@B180-jcm-09-00458]\] and attenuated the overexpression of NOX4, TGF-β, osteopontin, and MCP1 in the tubular cells induced by high glucose \[[@B181-jcm-09-00458]\].

The other two groups of anti-diabetic drugs are the dipeptidyl peptidase-4 (DPP-4) inhibitors and the glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RA). Several clinical trials suggest that these drugs possess the ability to improve renal function, possibly independently of the glycemic control \[[@B182-jcm-09-00458],[@B183-jcm-09-00458]\]. The renoprotection derived from the treatment with GLP-1RA and DPP-4 have been demonstrated in few experimental studies in animal models with DN. For instance, the DPP-4 inhibitor linagliptin exerts anti-inflammatory effects in the endothelium independently of the glycemic control \[[@B136-jcm-09-00458],[@B137-jcm-09-00458]\]. Diabetic patients treated with vildagliptin or sitagliptin presented a reduction in the levels of markers of inflammation \[[@B138-jcm-09-00458]\]. The group of GLP-1RA also exerts anti-inflammatory renoprotective actions. Exenatide treatment reduced albuminuria and macrophage infiltration in db/db mice (a model of type 2 diabetes) \[[@B139-jcm-09-00458]\] and attenuated albuminuria, mesangial expansion, and reduced the levels of inflammatory cytokines and adhesion molecules in type 1 diabetic rats \[[@B140-jcm-09-00458]\]. Recently, it has been demonstrated that sitagliptin and linagliptin can suppress the activity of NLRP3/inflammasome in an experimental model of renal injury \[[@B141-jcm-09-00458]\]. Potential anti-inflammatory properties for incretin modulators are also being investigated in clinical studies. In the clinical setting, type 2 diabetic patients treated with exenatide or dulaglutide presented reduced levels of CRP \[[@B142-jcm-09-00458]\]. The differential effects of diabetes therapy on blood and renal inflammation are being evaluated in several ongoing trials: GLP-1R agonist (exenatide or liraglutide) vs. a DPP4 inhibitor (NCT02150707) and liraglutide (LIRALBU; NCT02545738 and NCT01847313). The results of these studies will shed light on the anti-inflammatory effects of these treatments.

Pentoxifylline (PTX) (3,7-dimethyl-1-(5-oxohexyl)-3,7-dihydro-1*H*-purine-2,6-dione) is a methyl-xanthine derivative with hemorheological actions that has been clinically used for the treatment of claudication for more than 30 years \[[@B184-jcm-09-00458]\]. Importantly, this drug also presents anti-inflammatory properties that supports its potential application in the renoprotection of the diabetic patient. PTX aroused an early interest as a therapeutic agent in kidney disease due to its hemorheological properties and its potential to decrease intraglomerular pressure \[[@B185-jcm-09-00458],[@B186-jcm-09-00458]\]. Both clinical and experimental studies support antiproteinuric effect of PTX. Recently, the antiproteinuric property of PTX has been associated with anti-inflammatory capacities \[[@B187-jcm-09-00458],[@B188-jcm-09-00458],[@B189-jcm-09-00458],[@B190-jcm-09-00458],[@B191-jcm-09-00458],[@B192-jcm-09-00458],[@B193-jcm-09-00458]\].

PTX has a considerable modulating effect on several proinflammatory cytokines, which includes TNFα \[[@B153-jcm-09-00458],[@B187-jcm-09-00458]\], IL1, IL6, interferon γ \[[@B53-jcm-09-00458],[@B54-jcm-09-00458],[@B194-jcm-09-00458]\], and other molecules also related with the inflammatory phenomena like ICAM1, VCAM1, and CRP \[[@B195-jcm-09-00458],[@B196-jcm-09-00458]\]. Most of the clinical trials conducted to assess the renal effect of PTX in the diabetic setting have evidenced the protective effects of this compound by decreasing proteinuria and, in some cases, improving GFR \[[@B185-jcm-09-00458],[@B197-jcm-09-00458],[@B198-jcm-09-00458],[@B199-jcm-09-00458],[@B200-jcm-09-00458]\]. Importantly, in some of these studies \[[@B197-jcm-09-00458],[@B201-jcm-09-00458]\] the antiproteinuric effect of PTX was associated with significant reductions in TNFα levels. Similarly, clinical trials conducted in CKD patients with stage 3 or higher reported a stabilization of renal function and decreased circulating levels of TNFα, fibrinogen, and CRP after PTX treatment \[[@B202-jcm-09-00458]\], and reductions in proteinuria and urinary levels of TNFα and MCP1 after 1 year with add-on PTX to ARB background therapy \[[@B203-jcm-09-00458]\].

To date, the PREDIAN trial is the largest randomized controlled study evaluating the renoprotective effects of PTX in patients with DN under RAS blockade \[[@B143-jcm-09-00458]\]. The study comprised 169 type 2 diabetic subjects with CKD stages 3 or 4. The group of patients that received PTX on top of RAS blockade presented a reduction in the progression of renal disease after two years of follow-up. This reduction was accompanied by a decrease in proteinuria and urinary levels of TNFα. Two meta-analysis also pointed to the reduction of proinflammatory cytokines production as the most likely explanation for the antiproteinuric effect of PTX in patients with DN \[[@B144-jcm-09-00458]\] and concluded that PTX additively reduced proteinuria and TNFα in patients with DN patients receiving RAS inhibitors \[[@B145-jcm-09-00458]\]

PTX inhibits phosphodiesterases (PDEs) activity which, in turn, inactivate the intracellular messenger cyclic adenosine-3,5-monophosphate (cAMP). Therefore, PTX prevents the inactivation of cAMP, resulting in increased levels of cAMP which in turn upregulate protein kinase A (PKA)/cAMP response element-binding (CREB) protein thereby downregulating NF-κB signaling, which causes an anti-inflammatory response via the reduction of IL1, IL6, and TNFα synthesis \[[@B146-jcm-09-00458],[@B147-jcm-09-00458]\]. Moreover, PTX specifically inhibits the isoforms PDE3 and PDE4 which are mainly present in inflammatory cells \[[@B204-jcm-09-00458]\]. In several models of renal disease, PTX is able to attenuate proteinuria via the modulation of signaling pathways or components triggered by inflammatory cytokines \[[@B205-jcm-09-00458],[@B206-jcm-09-00458]\].

Other unexpected renoprotective effect of PTX on DN could come from the stimulation of factors directly related to kidney health. One of these factors is Klotho, a type I single-pass transmembrane protein predominantly expressed in the kidneys in a transmembrane and a soluble form \[[@B207-jcm-09-00458]\]. Many studies demonstrate the antiaging and nephroprotective effects of this protein. Importantly, patients with type 2 diabetes have low soluble Klotho levels \[[@B208-jcm-09-00458],[@B209-jcm-09-00458]\], and biopsies from patients with early stages of DN present diminished renal Klotho expression \[[@B210-jcm-09-00458]\]. These results point to Klotho as a potential early biomarker of renal impairment in type 2 diabetic patients \[[@B211-jcm-09-00458]\]. Interestingly, Klotho has an inverse relationship with inflammation. Thus, proinflammatory cytokines like TNFα and TWEAK (tumor necrosis factor--like weak inducer of apoptosis) exerts a NF-κB-mediated inhibition of renal Klotho expression \[[@B212-jcm-09-00458],[@B213-jcm-09-00458]\]. On the other hand, the addition of Klotho to renal and vascular endothelial cells reduces the synthesis of proinflammatory cytokines \[[@B213-jcm-09-00458]\] and the expression of TNFα-induced adhesion molecules \[[@B214-jcm-09-00458]\]. In the clinical setting, a post-hoc analysis of the PREDIAN trial \[[@B148-jcm-09-00458]\] reported that the administration of PTX reduced serum and urinary TNFα and increased serum and urinary Klotho levels in type 2 diabetic patients with CKD stages 3 and 4. Although the precise mechanisms are unknown, the Klotho stimulatory effect of PTX may come from its anti-inflammatory properties since PTX is able to reduce levels TWEAK, TNFα and albuminuria. Albuminuria causes tubular inflammation and renal injury \[[@B215-jcm-09-00458]\] and also directly reduces the expression of Klotho renal tubular cells \[[@B216-jcm-09-00458]\].

4. Conclusions {#sec4-jcm-09-00458}
==============

The burden of global diabetes is predicted to increase dramatically in the coming decades in parallel with the rising of obesity. One of the most important microvascular complications of diabetes is nephropathy, which substantially increases cardiovascular morbidity and mortality, determining a considerable impairment in the quality of this group of patients \[[@B217-jcm-09-00458]\]. Therefore, the need to find therapeutic targets and strategies for treating DN is clearly evident. Conventional treatments provide incomplete protection for the development of renal failure. Recent studies suggest that inflammation is a key factor in the development and progression of DN \[[@B218-jcm-09-00458]\]. Future therapeutic approaches with the ability to modulate inflammatory processes could be useful in the prevention or treatment of DN. These incoming therapies will be focused on the modulation of inflammatory pathways, including targets such as inflammatory cytokines, oxidative stress, JAK/STAT pathway, or NF-κB. Unfortunately, beyond the RAS blockade, there is limited experience regarding the inhibition of inflammatory molecules and pathways in the diabetic milieu. Therefore, further clinical trials are necessary to examine the potential renoprotective efficacy of the modulation of the inflammatory process and to understand how inflammatory pathways interact with other pathogenic factors in the context of DN.
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Main therapies for diabetic kidney disease with anti-inflammatory properties.

  Drug                                           Primary Target                                                      Outcomes                                                                                                               Anti-Inflammatory Effects                                                                               Ref.
  ---------------------------------------------- ------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  RAS blockers                                   Inhibition of ACE or blockade of angiotensin II receptor.           Reduce proteinuria and the progression of nephropathy.                                                                 Inhibition of NF-𝜅B, MCP1 gene expression, and macrophage infiltration.                                 \[[@B124-jcm-09-00458]\]
  Methyl bardoxolone                             Activation of Nrf2.                                                 Improved renal function in the short- and in the long-term. Stopped by serious adverse events.                         Inhibition of NF-𝜅B.                                                                                    \[[@B125-jcm-09-00458]\]
  Emanticap pegol                                Blockade of the MCP1 receptor.                                      Albuminuria reduction compared with baseline, but no significant difference with placebo                               Inhibition of MCP1.                                                                                     \[[@B126-jcm-09-00458]\]
  Baricitinib                                    Inhibition of the JAK/STAT pathway.                                 Albuminuria reduction in a dose dependent manner.                                                                      Reduction of inflammatory biomarkers like ICAM-1, TNFR1 and 2.                                          \[[@B85-jcm-09-00458]\]
  SGLT2 inhibitors                               Blockade of glucose reabsorption by SGLT2 at the proximal tubule.   Improved glycemic control. Slower progression of kidney disease and lower rates of clinically relevant renal events.   Reduction of inflammation by targeting the IL-1ß and reduction of hsCRP, TNF𝛼, IL6 and IFN-γ.           \[[@B127-jcm-09-00458],[@B128-jcm-09-00458],[@B129-jcm-09-00458],[@B130-jcm-09-00458],[@B131-jcm-09-00458],[@B132-jcm-09-00458],[@B133-jcm-09-00458],[@B134-jcm-09-00458],[@B135-jcm-09-00458]\]
  DPP-4 inhibitors and GLP-1 receptor agonists   Stimulation of glucose-dependent insulin release.                   Improved glycemic control and body weight reductions. Renoprotective actions.                                          Reduction in levels of inflammatory markers.                                                            \[[@B136-jcm-09-00458],[@B137-jcm-09-00458],[@B138-jcm-09-00458],[@B139-jcm-09-00458],[@B140-jcm-09-00458],[@B141-jcm-09-00458],[@B142-jcm-09-00458]\]
  Pentoxifylline                                 Inhibition of phosphodiesterases.                                   Reduced progression of renal disease and proteinuria.                                                                  Downregulation of NF-κB signaling and reduction of inflammatory biomarkers. Increased urinary Klotho.   \[[@B143-jcm-09-00458],[@B144-jcm-09-00458],[@B145-jcm-09-00458],[@B146-jcm-09-00458],[@B147-jcm-09-00458],[@B148-jcm-09-00458]\]
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